Marzia A. Scelsi

Welwyn Garden City, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Biomarker treatment effects in two phase 3 trials of gantenerumab.

Biomarker treatment effects in two phase 3 trials of gantenerumab.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: July 03, 2024

At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.

At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.

Journal: The journal of prevention of Alzheimer's disease

Published: May 06, 2024

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.

Journal: JAMA neurology

Published: April 29, 2024

Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.

Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.

Journal: NPJ digital medicine

Published: February 02, 2024

Validation of 3- and 5-point severity scales to assess ARIA-E.

Validation of 3- and 5-point severity scales to assess ARIA-E.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: July 19, 2023

A data-driven study of Alzheimer's disease related amyloid and tau pathology progression.

A data-driven study of Alzheimer's disease related amyloid and tau pathology progression.

Journal: Brain : a journal of neurology

Published: September 29, 2022

Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer's disease.

Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer's disease.

Journal: Alzheimer's research & therapy

Published: September 15, 2022

Comparing ARIA-E severity scales and effects of treatment management thresholds.

Comparing ARIA-E severity scales and effects of treatment management thresholds.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: August 15, 2022

Polygenic coronary artery disease association with brain atrophy in the cognitively impaired.

Polygenic coronary artery disease association with brain atrophy in the cognitively impaired.

Journal: Brain communications

Published: February 11, 2022

Glucose hypometabolism in the Auditory Pathway in Age Related Hearing Loss in the ADNI cohort.

Glucose hypometabolism in the Auditory Pathway in Age Related Hearing Loss in the ADNI cohort.

Journal: NeuroImage. Clinical

Published: March 24, 2021

Recent Consanguinity and Outbred Autozygosity Are Associated With Increased Risk of Late-Onset Alzheimer's Disease.

Recent Consanguinity and Outbred Autozygosity Are Associated With Increased Risk of Late-Onset Alzheimer's Disease.

Journal: Frontiers in genetics

Published: November 14, 2020

KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers.

KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers.

Journal: Neurobiology of aging

Published: September 17, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026